对生物活性玻璃（腻子）和富含血小板的血纤维蛋白治疗分叉病变的比较评估。
Journal of Oral Implantology
(
IF
1.5
)
Pub Date : 2016-06-09
, DOI:
10.1563/aaid-joi-d-16-00023
Shriparna Biswas
1
,
Savita Sambashivaiah
1
,
Rithesh Kulal
1
,
Shivaprasad Bilichodmath
1
,
Gregori M Kurtzman
2
Affiliation
1 Department of Periodontology, Rajarajeswari Dental College and Hospital, Karnataka, India.
2 Private practice, Silver Spring, Md.
这项研究的目的是比较第二代生物活性玻璃腻子生物材料与富含血小板的纤维蛋白在治疗II级分叉缺损中的作用。受试者为15位全身健康的患者（10位男性和5位女性，年龄20-50，平均年龄38.33），根据Glickman的分类具有20个下颌磨牙II级分叉缺损。将20个下颌磨牙分叉缺损按以下顺序随机分配：第一组，使用生物活性玻璃（NovaBone）骨移植腻子材料处理了10个分叉缺损。第二组，使用富含血小板的纤维蛋白（PRF）治疗10个分叉缺损。定制的丙烯酸支架在研究模型上制造，并修整到牙齿的高度轮廓，以作为测量的固定参考点。收集了以下测量值：牙龈指数，牙菌斑指数，垂直探测深度（从牙龈边缘到口袋底部），临床附着水平（CEJ到口袋底部）和水平分叉累及的深度（使用支架）。结果显示，两组在召回间隔时的牙龈指数（GI）和牙菌斑指数（PI）均有改善。两组的垂直和水平探测深度总体上都减小了。但是，在第三个月（P值= 0.0004），第六个月（P值= 0.00001）和第九个月末，油灰组（第一组）的垂直探测深度始终比PRF组（第二组）更多。月（P值= 0.0004）。我们的结论是，使用生物活性玻璃骨刺激性生物材料可产生卓越的临床效果，与自体血小板浓缩物相比，增加了II类分叉缺损的袋深度减少。我们发现的临床意义包括第二代腻子生物玻璃生物材料在分叉缺损中的易用性和出色的生物学性能。
"点击查看英文标题和摘要"
Comparative Evaluation of Bioactive Glass (Putty) and Platelet Rich Fibrin in Treating Furcation Defects.
The aim of this study was to compare a second-generation bioactive glass putty biomaterial against platelet rich fibrin in treating grade II furcation defects. Subjects were 15 systemically healthy patients (10 males and 5 females, ages 20-50 with a mean age of 38.33) with 20 mandibular molar class II furcation defects according to Glickman's classification. The 20 mandibular molar furcation defects were randomly allocated as follows: Group I, 10 furcation defects were treated using bioactive glass (NovaBone) bone graft putty material; Group II, 10 furcation defects were treated using platelet rich fibrin (PRF). Customized acrylic stents were fabricated on study casts and trimmed to the height contour of the teeth to serve as a fixed reference point for measurements. The following measurements were collected: gingival index, plaque index, vertical probing depth (from gingival margin to base of the pocket), clinical attachment level (CEJ to the base of the pocket), and horizontal probing depth of furcation involvement (using stent). Results showed that both groups had improvement in gingival index (GI) and plaque index (PI) at the recall intervals. There was an overall reduction in both vertical and horizontal probing depth in both groups; however, the Putty group (Group I) showed consistently more vertical probing depth reduction than the PRF group (Group II) at the end of third month (P-value = 0.0004), sixth month (P-value = 0.00001), and ninth month (P-value = 0.0004). Our conclusion was that use of bioactive glass osteostimulative biomaterial yields superior clinical results, including increased pocket depth reduction of class II furcation defects as compared to an autologous platelet concentrate. The clinical significance of our findings include the ease of use and superior biologic performance of second-generation putty bioglass biomaterials in furcation defects.
